Department of Anatomy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
Food Chem Toxicol. 2012 Mar;50(3-4):861-6. doi: 10.1016/j.fct.2011.11.009. Epub 2011 Nov 15.
We investigated the protective effects of two non-steroid anti-inflammatory drugs, indomethacin (COX-1 and COX-2 inhibitors) and nimesulide (specific COX-2 inhibitor) on the hepatic injury induced by lipopolysaccharide in d-galactosamine sensitized (Gal/LPS) mice. ICR male mice were injected with a single dose of Gal/LPS with or without pre-treatment of 3mg/kg indomethacin or 30 mg/kg nimesulide (single i.p. injection). Sixteen hours later, blood and liver tissues of mice were collected for histological, molecular, and biochemical analyses. Our results showed marked reduction of hepatic necrosis, serum ALT, and tissue TBARS levels in both indomethacin- and nimesulide-pre-treated mice when compared with Gal/LPS-treated mice. Western blot and RT-PCR analysis showed decreased levels of iNOS mRNA, iNOS protein, and nitrotyrosine formation in both COX inhibitor pre-treated groups when compared with Gal/LPS-treated group. There was an inverse relationship between COX-1 and COX-2 expressions, as well as between COX-2 and C/EBP-α expressions in COX inhibitors groups, Gal/LPS and control groups. COX inhibitors reduced the expression of TNF-α mRNA and the activity of NF-κB which were elevated by Gal/LPS treatment. We conclude that COX inhibitors protected the liver from Gal/LPS-induced hepatotoxicity. COX inhibitors could be considered as potential agents in the prevention of acute liver failure and sepsis.
我们研究了两种非甾体抗炎药(环氧化酶-1 和环氧化酶-2 抑制剂吲哚美辛和特异性环氧化酶-2 抑制剂尼美舒利)对 D-半乳糖胺敏化(Gal/LPS)小鼠脂多糖诱导肝损伤的保护作用。雄性 ICR 小鼠单次注射 Gal/LPS,或预先给予 3mg/kg 吲哚美辛或 30mg/kg 尼美舒利(单次腹腔注射)。16 小时后,收集小鼠的血液和肝脏组织进行组织学、分子和生化分析。结果表明,与 Gal/LPS 处理组相比,吲哚美辛和尼美舒利预处理组的肝坏死、血清 ALT 和组织 TBARS 水平明显降低。Western blot 和 RT-PCR 分析显示,与 Gal/LPS 处理组相比,两种 COX 抑制剂预处理组的 iNOS mRNA、iNOS 蛋白和硝基酪氨酸形成水平降低。在 COX 抑制剂组中,COX-1 和 COX-2 的表达以及 COX-2 和 C/EBP-α的表达呈负相关,在 COX 抑制剂组、Gal/LPS 和对照组中也是如此。COX 抑制剂降低了 Gal/LPS 处理引起的 TNF-α mRNA 表达和 NF-κB 活性的升高。我们得出结论,COX 抑制剂可保护肝脏免受 Gal/LPS 诱导的肝毒性。COX 抑制剂可被视为预防急性肝衰竭和脓毒症的潜在药物。